Suppliers and packagers for generic pharmaceutical drug: COLESEVELAM HYDROCHLORIDE

COLESEVELAM HYDROCHLORIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Alkem Labs Ltd	COLESEVELAM HYDROCHLORIDE	colesevelam hydrochloride	FOR SUSPENSION;ORAL	210316	ANDA	Bryant Ranch Prepack	63629-8860-1	30 PACKET in 1 CARTON (63629-8860-1) / 1 POWDER, FOR SUSPENSION in 1 PACKET	2019-05-09
Alkem Labs Ltd	COLESEVELAM HYDROCHLORIDE	colesevelam hydrochloride	FOR SUSPENSION;ORAL	210316	ANDA	Ascend Laboratories, LLC	67877-523-30	30 POWDER, FOR SUSPENSION in 1 PACKET (67877-523-30)	2019-05-09
Alkem Labs Ltd	COLESEVELAM HYDROCHLORIDE	colesevelam hydrochloride	FOR SUSPENSION;ORAL	210316	ANDA	Bryant Ranch Prepack	72162-1847-2	30 POWDER, FOR SUSPENSION in 1 PACKET (72162-1847-2)	2019-05-09
Glenmark Pharms Ltd	COLESEVELAM HYDROCHLORIDE	colesevelam hydrochloride	FOR SUSPENSION;ORAL	202190	ANDA	Glenmark Pharmaceuticals Inc.,USA	68462-620-30	30 PACKET in 1 BOX (68462-620-30) / 1 POWDER, FOR SUSPENSION in 1 PACKET	2018-07-16
Impax	COLESEVELAM HYDROCHLORIDE	colesevelam hydrochloride	FOR SUSPENSION;ORAL	212886	ANDA	Amneal Pharmaceuticals of New York LLC	0115-1864-18	30 PACKET in 1 CARTON (0115-1864-18) / 1 FOR SUSPENSION in 1 PACKET (0115-1864-30)	2023-01-20
Cosette	WELCHOL	colesevelam hydrochloride	FOR SUSPENSION;ORAL	022362	NDA	Cosette Pharmaceuticals, Inc.	0713-0880-30	30 PACKET in 1 CARTON (0713-0880-30) / 1 FOR SUSPENSION in 1 PACKET	2022-09-01
Cosette	WELCHOL	colesevelam hydrochloride	FOR SUSPENSION;ORAL	022362	NDA	Cosette Pharmaceuticals, Inc.	0713-0935-30	30 PACKET in 1 CARTON (0713-0935-30) / 1 FOR SUSPENSION in 1 PACKET	2022-08-01

Colesevelam Hydrochloride Suppliers

Last updated: February 19, 2026

This report details key suppliers of Colesevelam Hydrochloride, a bile acid sequestrant used to treat hyperlipidemia and type 2 diabetes. Analysis focuses on production capacity, regulatory compliance, and market presence based on publicly available information and patent filings.

Who are the primary manufacturers and suppliers of Colesevelam Hydrochloride?

The production of Colesevelam Hydrochloride involves specialized chemical synthesis and strict adherence to Good Manufacturing Practices (GMP). Several entities are identified as significant players in the supply chain, ranging from originator manufacturers to generic producers and contract manufacturing organizations (CMOs).

• Daiichi Sankyo: The originator of Colesevelam Hydrochloride, marketed as Welchol. Daiichi Sankyo maintains a significant presence in the supply chain, controlling aspects of both manufacturing and distribution for its branded product. Their proprietary manufacturing processes and patents influence market access and competitor entry.
• Teva Pharmaceuticals: A major generic pharmaceutical company that produces a generic version of Colesevelam Hydrochloride. Teva's entry into the market after patent expirations has increased supply and competition.
• Dr. Reddy's Laboratories: Another significant generic manufacturer with a presence in the Colesevelam Hydrochloride market. Dr. Reddy's often leverages its established API manufacturing capabilities and global distribution networks.
• Hetero Drugs: A large Indian pharmaceutical company that manufactures and supplies Active Pharmaceutical Ingredients (APIs) and finished dosage forms, including Colesevelam Hydrochloride. Hetero is known for its substantial API production capacity.
• Amneal Pharmaceuticals: Engaged in the development and manufacturing of generic drugs, Amneal offers Colesevelam Hydrochloride. Their operations include API sourcing and finished product formulation.
• Mylan (now part of Viatris): Mylan, prior to its merger with Upjohn to form Viatris, was a notable supplier of generic Colesevelam Hydrochloride. Viatris continues this supply chain.

The supply chain is further supported by companies specializing in the synthesis of key intermediates and the custom manufacturing of the final API under contract. These CMOs, while not always directly marketing the finished product, are critical to the overall availability of Colesevelam Hydrochloride.

What are the key regulatory considerations for Colesevelam Hydrochloride suppliers?

Suppliers of Colesevelam Hydrochloride must comply with stringent regulatory requirements from agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national health authorities. Compliance spans API manufacturing, finished drug product formulation, quality control, and distribution.

• Current Good Manufacturing Practices (cGMP): All manufacturing facilities must adhere to cGMP guidelines. This includes rigorous standards for facility design, equipment, personnel training, raw material control, process validation, and quality assurance. FDA inspections and audits are standard for ensuring compliance. For example, FDA Form 483 observations highlight deviations from cGMP and require corrective actions [1].
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies like the FDA. These confidential documents provide detailed information about the manufacturing process, facilities, quality controls, and stability of the API. Drug product manufacturers reference these DMFs in their marketing applications (e.g., Abbreviated New Drug Applications - ANDAs).
• ANDA Filings: Generic manufacturers must submit ANDAs to the FDA demonstrating bioequivalence to the reference listed drug (Welchol). This process requires extensive data on the generic product's API and finished dosage form.
• Impurity Profiling and Control: Suppliers must meticulously identify, quantify, and control impurities in the API and finished product. Regulatory bodies set strict limits for known and unknown impurities, including genotoxic impurities. The qualification of impurities is a critical aspect of regulatory submissions.
• Stability Studies: Comprehensive stability studies are required to establish the shelf-life of both the API and the finished drug product under various storage conditions. These studies inform packaging, labeling, and expiration dating.
• Supply Chain Integrity: Regulators increasingly scrutinize the entire pharmaceutical supply chain to prevent counterfeiting and ensure product quality. This includes supplier qualification, robust change control procedures, and secure logistics.
• International Harmonization: While regulations vary by region, efforts towards international harmonization (e.g., through the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - ICH) influence global compliance standards for quality, safety, and efficacy.

What is the patent landscape for Colesevelam Hydrochloride?

The patent landscape for Colesevelam Hydrochloride is characterized by patents protecting the compound itself, its synthesis, and its therapeutic uses. As patents expire, generic competition emerges, impacting market dynamics and pricing.

• Composition of Matter Patents: The initial patents typically covered the novel chemical entity, Colesevelam Hydrochloride. These patents have largely expired, allowing for generic development. U.S. Patent 5,693,676, for instance, covers colesevelam and related polymers [2].
• Method of Synthesis Patents: Patents also protect specific methods for synthesizing Colesevelam Hydrochloride. Generic manufacturers often develop alternative, non-infringing synthesis routes to bypass existing patents and gain market entry. The complexity and cost of these alternative routes can influence a company's ability to compete.
• Formulation and Polymorph Patents: Patents may cover specific pharmaceutical formulations (e.g., tablet coatings, excipient combinations) or different crystalline forms (polymorphs) of Colesevelam Hydrochloride. These can extend market exclusivity for the innovator or provide differentiation for generic products.
• Use Patents: Patents related to specific therapeutic uses of Colesevelam Hydrochloride, such as its efficacy in treating certain types of hyperlipidemia or its impact on glycemic control in type 2 diabetes, can also exist. These can be challenged by generic manufacturers if they are deemed obvious or not sufficiently novel.
• Exclusivity Periods: Beyond patent protection, regulatory exclusivities (e.g., Hatch-Waxman exclusivity in the U.S.) can grant periods of market protection for new drug applications or new uses approved by the FDA.

The expiration of key patents for Colesevelam Hydrochloride has led to a more competitive generic market. Companies actively monitor patent landscapes to identify opportunities for generic development and to manage potential patent litigation. For example, the expiry of foundational patents has permitted numerous ANDA filings by generic manufacturers.

What are the principal manufacturing processes and technologies employed?

The manufacturing of Colesevelam Hydrochloride involves a multi-step chemical synthesis and polymerization process. Key aspects include the synthesis of the precursor polymer and its subsequent functionalization.

• Epichlorohydrin Chemistry: A core aspect of Colesevelam Hydrochloride synthesis involves the reaction of epichlorohydrin with amines to form cross-linked polyamines. This is a common method for producing polymeric structures with amine functionalities.
• Cross-linking and Polymerization: The process involves creating a three-dimensional polymeric network. This is typically achieved through the polymerization of monomers or the cross-linking of pre-existing polymer chains. The degree of cross-linking is a critical parameter affecting the physical properties of the final product.
• Functionalization with Amines: The polymer is then functionalized with amine groups, specifically amine groups that will become quaternary ammonium groups in the final product. This functionalization step is crucial for the drug's mechanism of action, as these positively charged groups bind to negatively charged bile acids.
• Salt Formation: The final step often involves the formation of the hydrochloride salt of the functionalized polymer. This provides a stable, water-insoluble form suitable for oral administration.
• Purification and Isolation: Rigorous purification steps are essential to remove unreacted starting materials, byproducts, and residual solvents. Techniques such as washing, filtration, and drying are employed. The final API must meet strict purity specifications.
• Particle Size Control: For oral dosage forms, controlling the particle size distribution of the Colesevelam Hydrochloride API is important for factors such as dissolution rate and bioavailability. Milling or micronization techniques may be used.
• Quality Control and Analytical Testing: Extensive in-process and final product testing is conducted using techniques such as High-Performance Liquid Chromatography (HPLC) for purity and assay, Fourier-Transform Infrared Spectroscopy (FTIR) for identification, and titration for salt content.

Suppliers may employ proprietary variations of these processes to optimize yield, purity, and cost-effectiveness. The development of more efficient or environmentally friendly synthesis routes is an ongoing area of interest in pharmaceutical manufacturing.

What is the market demand and competitive landscape for Colesevelam Hydrochloride?

The market for Colesevelam Hydrochloride is driven by its approved therapeutic indications and the prevalence of the diseases it treats. The competitive landscape has evolved significantly with the introduction of generic alternatives.

• Therapeutic Indications: Colesevelam Hydrochloride is primarily prescribed for:
  • Reduction of low-density lipoprotein cholesterol (LDL-C) in adult patients with primary hyperlipidemia.
  • Adjunctive therapy to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus.
  • In some markets, it may also be indicated for reducing the risk of primary or secondary cardiovascular events among patients with established cardiovascular disease and type 2 diabetes.
• Prevalence of Target Diseases: The growing prevalence of hyperlipidemia and type 2 diabetes globally directly influences the demand for Colesevelam Hydrochloride and other lipid-lowering and anti-diabetic agents. Factors such as aging populations, lifestyle changes, and increased diagnostic rates contribute to market growth.
• Genericization Impact: The entry of generic Colesevelam Hydrochloride products has led to significant price erosion compared to the originator brand (Welchol). This has increased patient access and overall volume but reduced revenue for individual suppliers.
• Competitive Product Set: Colesevelam Hydrochloride competes with other classes of lipid-lowering drugs, including statins, ezetimibe, PCSK9 inhibitors, and fibrates. It also competes with other anti-diabetic medications, including metformin, DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors. Its unique mechanism as a bile acid sequestrant provides a distinct position in the therapeutic armamentarium, particularly for patients intolerant to statins or as an add-on therapy.
• Market Share Distribution: Following patent expiries, generic manufacturers hold substantial market share. The market is fragmented among several key generic players, with price and supply reliability being key competitive differentiators.
• Geographic Markets: Demand is strong in developed markets like the United States and Europe, where healthcare access and prescription rates for chronic disease management are high. Emerging markets represent potential growth areas as access to advanced pharmaceuticals increases.

The long-term market demand will be influenced by the development of new therapeutic agents, evolving treatment guidelines, and cost-effectiveness considerations in healthcare systems.

Key Takeaways

• The supply of Colesevelam Hydrochloride is robust, with originator Daiichi Sankyo and several generic manufacturers including Teva Pharmaceuticals, Dr. Reddy's Laboratories, Hetero Drugs, Amneal Pharmaceuticals, and Viatris being principal entities.
• Strict regulatory compliance with cGMP, accurate DMF filings, and rigorous impurity control are paramount for all suppliers.
• The patent landscape has shifted from composition of matter to formulation and process patents, with foundational patents having expired, enabling generic competition.
• Manufacturing involves multi-step chemical synthesis and polymerization, with a focus on epichlorohydrin chemistry, cross-linking, and amine functionalization.
• Market demand is driven by the prevalence of hyperlipidemia and type 2 diabetes, with significant price competition and market share fragmentation resulting from generic entry.

Frequently Asked Questions

What is the primary mechanism of action of Colesevelam Hydrochloride?

Colesevelam Hydrochloride is a non-absorbed, polymeric bile acid sequestrant. It binds to bile acids in the intestine, preventing their reabsorption and promoting their excretion. This leads to increased hepatic synthesis of bile acids from cholesterol, which in turn reduces circulating LDL-C levels. In type 2 diabetes, this process also impacts glucose metabolism.

What are the main indications for Colesevelam Hydrochloride?

The primary indications are the reduction of low-density lipoprotein cholesterol (LDL-C) in adult patients with primary hyperlipidemia and as an adjunctive therapy to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus.

How does Colesevelam Hydrochloride differ from statins?

Colesevelam Hydrochloride has a different mechanism of action than statins. Statins inhibit cholesterol synthesis in the liver, whereas Colesevelam Hydrochloride works in the intestine by binding to bile acids. This distinction allows Colesevelam Hydrochloride to be used as an alternative or add-on therapy for patients who cannot tolerate statins or require additional LDL-C lowering.

What are the potential side effects associated with Colesevelam Hydrochloride?

Common side effects include constipation, abdominal pain, diarrhea, nausea, and vomiting. It can also interfere with the absorption of certain fat-soluble vitamins (A, D, E, and K) and other medications, necessitating careful timing of administration.

What is the typical dosage form and strength of Colesevelam Hydrochloride?

Colesevelam Hydrochloride is typically available as oral tablets. Common strengths include 625 mg tablets. The dosage varies depending on the indication and patient response.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Inspections, Compliance, Enforcement & Criminal Investigations. Retrieved from https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations

[2] U.S. Patent 5,693,676 A. (1997). Cross-linked amine polymers for binding bile acids. Retrieved from USPTO Patent Database.